That said, as addition of the IL-1β ligand allowed for specific targeting of the BoNT/D protease into IL-1R-expressing macrophages and enhancing the efficacy of this modified BoNT/D, we believe that our recombinant targeted toxin would be a potent and effective treatment for RA. The gene discussed is IL1R1; the disease is rheumatoid arthritis.